The system has already been implemented in a working prototype by Verily’s Silicon Valley team, though the company is exploring multiple form factors for the device, according to the report.
Commercialization of the moonshot device, which CNBC reports will function by “exploding” needles into the wearers skin and then retracting them using magnets, could still be years away and faces regulatory and technical hurdles.
The most likely use for the device would be to keep track of blood-based biomarkers during clinical trial monitoring, according to the report, but the company is still exploring other possible uses.
The blood-drawing watch device could be designed to contain several compartments designed to store and measure small blood samples to analyze it for signals, according to the report.
The device could also be used as a replacement for traditional blood draws in certain medical settings, CNBC reports.
Verily has not yet lined up a partner for the development, according to the report, which would require a significant R&D investment and would have to meet a number of FDA regulatory hurdles.
Last September, a new study emerged showing that Verily is developing a new artificial-intelligence powered test that searches for indicators of heart disease risk present in retina images.
Heidi Dohse was diagnosed with a rare arrhythmia in 1982 and has been 100% pacemaker dependent for over 30 years. With the help of wearable devices, she has been able to pursue her dream to become a competitive cyclist.
You can hear her story and more when you register for DeviceTalks Boston, October 8-10.
Use code FINISHLINE to save an additional 10%.